Abbott Laboratories
Research Abbott Laboratories (ABT) on Bullrun: valuation model: 10.2% undervalued, market cap USD 161.48B, P/E 25.8, dividend yield 2.6%. Explore financials, valuation history, model signals, and stock context.
Key Metrics
- TickerABT
- ExchangeNYSE
- CountryUnited States
- SectorHealthcare
- IndustryMedical Devices
- CurrencyUSD
- Valuation signal10.2% undervalued
- Market capUSD 161.48B
- P/E25.8
- Dividend yield2.6%
- Financial periodFY2025
- RevenueUSD 44.33B
- Revenue growth5.7%
- Net incomeUSD 6.52B
- Free cash flowUSD 7.40B
- Gross margin56.4%
Valuation Snapshot
Bullrun's latest valuation model marks Abbott Laboratories as 10.2% undervalued; latest market cap is USD 161.48B; P/E is 25.8; dividend yield is 2.6%.
About Abbott Laboratories
Abbott Laboratories, together with its subsidiaries, discovers, develops, manufactures, and sells health care products worldwide. It operates in four segments: Established Pharmaceutical Products, Diagnostic Products, Nutritional Products, and Medical Devices.
Frequently asked questions
Is Abbott Laboratories overvalued or undervalued?
Bullrun's valuation model currently marks Abbott Laboratories as 10.2% undervalued.
What is Abbott Laboratories's market cap?
Abbott Laboratories's market capitalization is USD 161.48B.
What is Abbott Laboratories's P/E ratio?
Abbott Laboratories's price-to-earnings (P/E) ratio is 25.8.
Does Abbott Laboratories pay a dividend?
Abbott Laboratories has a dividend yield of 2.6%.
What does Abbott Laboratories do?
Abbott Laboratories, together with its subsidiaries, discovers, develops, manufactures, and sells health care products worldwide. It operates in four segments: Established Pharmaceutical Products, Diagnostic Products, Nutritional Products, and Medical Devices.